
---
title: '呼吸道合胞病毒疫苗和单抗最新研究进展（14）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://blog.sciencenet.cn/static/ueditor/themes/default/images/spacer.gif'
author: 科学网
comments: false
date: Mon, 05 Sep 2022 11:53:00 GMT
thumbnail: 'https://blog.sciencenet.cn/static/ueditor/themes/default/images/spacer.gif'
---

<div>   
<p style="margin-top:31px;margin-right:0;margin-bottom:31px;margin-left:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px"><strong><span style="color: #231F20; letter-spacing: 1px; font-size: 36px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">呼吸道合胞病毒预防制剂曙光在前</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 36px;background: #FFFFFF">:　</span></strong></p><p style="margin-top:60px;margin-right:0;margin-bottom:84px;margin-left:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px"><strong><span style="color: #231F20; letter-spacing: 1px; font-size: 36px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">疫苗和单克隆抗体百舸争流</span></strong></p><p style="margin: 60px 0px 84px; padding: 0px; line-height: normal;"><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">前言：</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">　</span></strong></p><p style="margin: 60px 0px 84px; padding: 0px; line-height: normal;"><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">        新冠病毒大流行的将近３年，也是世界疫苗行业突飞猛进、疫苗研发技术日新月异、硕果累累的３年。疫苗制备的多种技术途径都得到深度开发，若干种新兴的技术途径如mRNA疫苗获得了空前的成功，在世界各地大行其道，在多种传染病以及癌症和其他慢性病的防治领域都在不断开花结果。</span></strong></p><p style="margin: 60px 0px 84px; padding: 0px; line-height: normal;"><strong>　　　　</strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">呼吸道合胞病毒（</span></strong><strong><span style="text-decoration-line: underline; font-family: Shaker2Lancet-Bold; color: #231F20; letter-spacing: 1px; font-size: 24px;">Respiratory syncytial virus，</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="text-decoration-line: underline; color: #231F20; letter-spacing: 1px; font-size: 24px; font-family: Shaker2Lancet-Bold;">）</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">是一种历史悠久、危害极大的传染病，其疫苗的研发已经有四十年的历史， 但最初开发的疫苗反而会引发</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">疫苗相关性呼吸道疾病（VAERD，Vaccine-associated enhanced respiratory diseases</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px">）</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">，即未接触过</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的儿童在接种了疫苗后，如果再接触到该病毒反而会发生更严重的</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疾病。诸如此类的问题导致针对</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗一直未能上市。乘新冠病毒疫苗大跃进的东风，已赚得盆满钵满的疫苗巨头如</span></strong><strong><span style="text-decoration-line: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">辉瑞（Pfizer)</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">、</span></strong><strong><span style="text-decoration-line: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">莫德纳（Moderna</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">）和</span></strong><strong><span style="text-decoration-line: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">葛兰素史克(GSK)</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">等目前都在</span></strong><strong><span style="text-decoration-line: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗开发上快马加鞭，有望在较短时间内取得重大突破。</span></strong></p><p style="margin: 30px 0px 54px; text-indent: 0px; padding: 0px; background: rgb(255, 255, 255); line-height: normal;"><strong>　　　　</strong><strong><span style="text-decoration: underline; color: #333333; letter-spacing: 0px; font-size: 24px; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疫苗和单克隆抗体研究领域来自世界各地的顶级研究人员（约５０人）近期联名在国际著名专业杂志《</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #FF0000;letter-spacing: 0;font-size: 24px">Lancet</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"> Infect Dis》上发表综述论文，介绍相关最新研究进展（见</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #222222;letter-spacing: 0;font-size: 24px">参考文献</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">），本博客将分数次介绍此综述的主要内容。</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 24px">目录：</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">摘要</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">一</span>.　前言</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">二</span>.　方法</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">三</span>.　教训（Lessons learned）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">四</span>.　减毒活疫苗（live attenuated vaccines，LAVs ）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">五</span>.　嵌合疫苗（Chimeric ）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">六</span>.　亚单位疫苗（Subunit）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">七</span>.　基于颗粒的疫苗（Particle-based ）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">八</span>.　核酸疫苗（Nucleic acid）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">九</span>.　重组载体疫苗（Recombinant vectors）</span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:39px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:21px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">十</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">单克隆抗体（MAbs）</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px">十一.　讨论</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 1px;font-size: 21px"></span></strong></p><p style="line-height: 200%"><span style="font-size: 36px;"><strong><span style="font-family: ScalaLancetPro; line-height: 200%; color: #231F20;"><strong style="white-space: normal;"><span style="line-height: 200%; color: #231F20; letter-spacing: 1px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">十一.　讨论</span></strong></span></strong></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在过去的十年中，</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗的格局发生了重大转变，疫苗设计从</span><span style=";font-family:SimSun;line-height:200%;color:#231F20;font-size:19px">仅凭</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">经验到更具理性。我们在几年前的两篇综述中，曾描述</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗的动态情况，包括多个已进展到临床试验后期的失败。这些失败为今后的成功奠定了基础，指引了</span><strong><span style="text-decoration: underline; line-height: 200%; color: #0000FF; font-size: 19px; font-family: ScalaLancetPro;">疫苗开发</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0000FF; font-size: 19px; font-family: ScalaLancetPro;">的方向</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">:</span><strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">支持将</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">pre-F</span><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（前融合蛋白）</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">作为疫苗抗原，强调在一个以上的</span><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">季节进行疫苗试验的重要性，提供保护性免疫反应的知识，强调监测病毒对单克隆抗体的耐药性的重要性，以及强调设置有对照的人类感染模型对降低</span><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">疫苗开发风险的价值。</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">处于后期开发阶段的候选疫苗数量正在增加</span>:截至2015年和2018年，分别只有一种单抗和一种孕产妇候选疫苗处于第三期临床试验阶段的开发。由于未能达到试验的主要终点，这两种药物的开发都被停止了，但已经将吸取的重要教训纳入到当前的试验。</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">对</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 20px">RSV</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">中和抗原表位的更</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">深入</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">理解导致</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">有</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">9种候选疫苗</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">都已进入</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">3期</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">临床</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">试验</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">的</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">快速扩展</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">(图4)。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#0000FF;font-size:19px">预防似乎已出现在地平线上，预计单抗制品</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 20px">nirsevimab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#0000FF;font-size:19px"><span style="font-family:ScalaLancetPro">将在</span>2022年7月以后的12至24个月内进入市场。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在此项目获得<span style="font-family:ScalaLancetPro">批准之后，可能很快就会批准一种孕产妇疫苗和一种老年人疫苗</span>(亚单位<span style="font-family:ScalaLancetPro">疫苗、载体疫苗和处于后期试验阶段的核酸疫苗</span>)。在这种情况下，将出现多个</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">候选疫苗被批准的情况。如果所有正在进行的</span>3期临床试验都产生了积极的结果，相对有效性和安全性试验数据、接种策略和成本可能会决定不同的孕产妇和老年人候选疫苗的接种情况。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">尽管新一代抗体已获批准，但原有的单抗制品</span><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">palivizumab</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">可能会继续留在市场上，直到延长半衰期的单抗在全球市场获得准入，因为单抗供应可能无法满足全球需求。</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">palivizumab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">已<span style="font-family:ScalaLancetPro">上市</span>20年，</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">对</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">palivizumab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的耐药性仍然可以忽略不计。因此，尽管存在需要多剂量的接种方案和成本问题，但</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">palivizumab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">可能作为一种备用预防策略，同时等待单抗在高收入国家中使用后的全球实时病毒耐药性数据。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">在婴儿免疫预防和</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">孕产妇</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">疫苗都上市的情况下，重要的是要考虑如何</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">使</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">这两种旨在保护幼儿的预防战略</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">能</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">共存。</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">孕产妇疫苗和婴儿免疫预防可能在预防婴儿期严重</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">感染方面发挥互补作用。即使孕产妇疫苗获得批准，单抗也有明确的使用需求:单抗有望保护早产儿和足月婴儿，可能能够提供比孕产妇疫苗更长的保护时间，可以灵活应用于</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">季节性变化的地方，并可以在母体没有进行免疫接种的情况下实施。也有一种孕产妇疫苗与已批准的单抗共存的使用案例。孕产妇主动接种疫苗可<span style="font-family:ScalaLancetPro">提供广泛的保护</span>;然而，目前尚不清楚孕产妇接种疫苗是否可一直持续到随后的再次怀孕，以及加强接种疫苗是否能提供更强的保护。孕产妇接种疫苗也可能为不愿给婴儿接种疫苗的父母提供一种选择。最后，在病毒对单克隆抗体产生耐药性或因相应生物制品生产成本过高的限制而只能给特定人群使用的情况下，孕产妇疫苗可作为一种备用疫苗。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">在低收入和中等收入国家</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">（</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">LMICs</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">）</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">，单抗</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">特别是</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">可</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">在以下几种情况下对</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">年幼婴儿</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">提供</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">保护</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">:如果在疫苗可用之前有相当长的时间间隔，如果他们的母亲没有接种疫苗，如果接种后没有足够的时间产生免疫反应(即早产儿)。<a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a><span style="font-family:ScalaLancetPro">低收入和中等收入国家甚至可能更喜欢单克隆抗体而不是孕产妇免疫接种，因为扩大免疫规划的覆盖率可能更高，更容易实施。然而，低收入和中等收入国家的实施面临一些挑战，包括</span>(1)</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">全年流行(出生时使用单抗可能比季节性使用更具成本效益)，(2)施用的灵活<span style="font-family:ScalaLancetPro">性取决于多剂量小瓶的使用和环境温度下的稳定性，</span>(3)缺乏关于低收入和中等收入国家</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">负担和卫生保健需求<span style="font-family:ScalaLancetPro">的数据，</span>(4)在</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">nirsevimab</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">上市的情况下进行试验设计</span>(需要大样本)，(5)低收入和中等收入国家病毒耐药性监测的潜在局限性(尽管自COVID-19以来可能有所增强)。因此，单抗可能对中低收入国家产生很大影响，但实施方面的挑战仍然存在。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">通过</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">孕产妇</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 19px">免疫接种或单抗免疫预防获得的被动抗体将随着时间的推移而减少，此时用于主动免疫接种的儿科疫苗可能发挥重要作用。</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">减毒活疫苗或可复制的载体疫苗不会导致呼吸道疾病的增强;通过鼻内途径接种，它们在母体抗体存在的情况下仍具有免疫原性。因此，这些主动免疫接种方法对年龄较大的儿童组可能是安全的，将作为婴儿免疫预防和孕产妇疫苗的补充。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#0000FF;font-size:19px">虽然多种</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #0000FF;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#0000FF;font-size:19px">疫苗获得批准已是指日可待，但在世界范围内获得疫苗仍然存在一些障碍。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">需要在全球范围内进行具有代表性的试验，并需要在疾病负担最高的国家进行疫苗试验，因为根据观察，针对</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">和其他病原体的疫苗在低收入和高收入国家之间的疗效可能不同。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"> <span style="font-family:ScalaLancetPro">由于缺乏针对艾滋病毒和疟疾高发人群的试验数据，以及撒哈拉以南非洲地区</span>药物监管部门在申请提交和批准之间的滞后，低收入和中等收入国家获得监管部门批准的药物的时间可能会推迟。</span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">全球疫苗免疫联盟</span>(GAVI)</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的疫苗投资战略包括</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">，这对于在有资格获得全球疫苗免疫联盟支持的国家提供</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">预防具有重要意义。差别定价可能是没有资格获得全球疫苗免疫联盟支持的国家的一个重要考虑因素。在全球获取方面面临的其他挑战包括在孕产妇需要疫苗增强接种的情况下如何衡量保护效力。</span></p><p style="margin-left: 0;text-indent: 46px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗接种后的保护相关因子尚未完全确定，测量</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗接种后保护作用的简单工具尚不存在。通过持续的基因监测来评估</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">预防的可持续性是很重要的。病毒耐药性的发展与婴儿单克隆抗体免疫预防最为相关。针对不同表位的单抗鸡尾酒可能有助于防止病毒耐药性的出现。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">然而，目前还没有正在进行的采用多种单抗的临床试验，这可能会妨碍监管机构批准鸡尾酒药物，而目前已有批准用于预防</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">SARS-CoV-2<span style="font-family:ScalaLancetPro">（新冠病毒）</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的鸡尾酒单抗。最后，患者、决策者和卫生保健提供者对</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 20px">RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的认识还很有限，需要对产品进行进一步的成本效益研究。这些与全球疫苗实施有关的知识差距是未来需要优先研究的重要项目(专栏)。</span></p><p><span style=";font-family:ScalaLancetPro;color:#231F20;font-size:19px"></span></p><p style="text-autospace:ideograph-numeric;text-align:justify;text-justify:inter-ideograph;line-height:200%"><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">专栏</span></strong><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">:</span></strong><strong>　</strong><span style="color: #00B050;"><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">RSV</span></strong></span><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">疫苗和单克隆抗体未来</span></strong><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">的</span></strong><strong><span style="color: #7030A0; font-family: ScalaLancetPro; line-height: 200%; font-size: 24px;">研究重点</span></strong></span></p><p style="margin-left: 0;text-indent: 46px;line-height: 200%"><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="background: #FFFF00; line-height: 200%; letter-spacing: 0px; font-size: 20px; color: #7030A0; font-family: "Microsoft YaHei UI";">•</span></strong><strong><span style="background: #FFFF00; line-height: 200%; letter-spacing: 0px; font-size: 20px; color: #7030A0; font-family: "Microsoft YaHei UI";">增进对</span></strong><strong><span style="background: #FFFF00; font-family: "Microsoft YaHei UI"; line-height: 200%; color: #069A2E; letter-spacing: 0px; font-size: 20px;">RSV</span></strong><strong><span style="background: #FFFF00; line-height: 200%; letter-spacing: 0px; font-size: 20px; color: #7030A0; font-family: "Microsoft YaHei UI";">的认</span></strong><strong><span style="background: #FFFF00; line-height: 200%; letter-spacing: 0px; font-size: 20px; color: #7030A0; font-family: "Microsoft YaHei UI";">知</span></strong><strong><span style="background: #FFFF00; line-height: 200%; letter-spacing: 0px; font-size: 20px; color: #7030A0; font-family: "Microsoft YaHei UI";">。</span></strong></span></p><p style="margin-left: 0;text-indent: 46px;line-height: 200%"><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">•了解在世界不同地区预防<strong style="color: rgb(112, 48, 160); text-indent: 46px; white-space: normal;"><span style="font-family: "Microsoft YaHei UI"; line-height: 40px; color: #069A2E; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">RSV</span></strong>的成本效益</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">。</span></strong></span></p><p style="margin-left: 0;text-indent: 46px;line-height: 200%"><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">•确定<strong style="color: rgb(112, 48, 160); text-indent: 46px; white-space: normal;"><span style="font-family: "Microsoft YaHei UI"; line-height: 40px; color: #069A2E; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">RSV</span></strong>的保护相关</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">因子。</span></strong></span></p><p style="margin-left: 0;text-indent: 46px;line-height: 200%"><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">•确定在低收入至中等收入国家预防<strong style="color: rgb(112, 48, 160); text-indent: 46px; white-space: normal;"><span style="font-family: "Microsoft YaHei UI"; line-height: 40px; color: #069A2E; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">RSV</span></strong>的有效性</span></strong><strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">。</span></strong></span></p><p><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="letter-spacing: 0px; font-size: 20px; background: #FFFFFF; color: #7030A0; font-family: "Microsoft YaHei UI";">　　 </span></strong><span style="color: #7030A0; background-color: #FFFF00;"><strong><span style="letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";"> •<strong style="color: rgb(112, 48, 160); text-indent: 46px; white-space: normal;"><span style="font-family: "Microsoft YaHei UI"; line-height: 40px; color: #069A2E; letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">RSV</span></strong></span></strong><strong><span style="letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">的遗传学</span></strong><strong><span style="letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">监测</span></strong><strong><span style="letter-spacing: 0px; font-size: 20px; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: #7030A0; font-family: "Microsoft YaHei UI";">。</span></strong></span></span></p><p><br></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"> </span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">总的来说，我们正处于疫苗和单抗开发的令人兴奋的阶段，</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 20px">RSV</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">的预防是可以实现的。具有互补价值、独特优势和用</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">途</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">场景的多种免疫策略很可能将</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">重新</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">塑造</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 20px">RSV</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">的</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">预防格局。</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">为确保在全球范围内易于获取，需要采取紧急措施，克服衡量保护效力的挑战<span style="font-family:ScalaLancetPro">、监测病毒耐药性以及优先考虑</span>LMIC（低和中等收入国家）的获取和负担能力等挑战。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 19px">（全文完）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 19px">参考文献：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 16px">Natalie I Mazur,</span></em><em>　</em><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 16px">et al., </span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 16px">Respiratory syncytial virus prevention within reach:</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 16px"> the vaccine and monoclonal antibody landscape, </span></strong><em><span style="font-family: Shaker2Lancet-Bold;color: #FF0000;letter-spacing: 0;font-size: 16px">Lancet Infect Dis</span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 16px"><span style="font-family:Shaker2Lancet-Bold">，</span> Published online August 8, 2022， </span></strong><span style="font-family: Tahoma;color: #505050;letter-spacing: 0;font-size: 16px">DOI: </span><a href="https://doi.org/10.1016/S1473-3099(22)00291-2" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px">https://doi.org/10.1016/S1473-3099(22)00291-2</span></a><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 16px">，</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext" target="_blank"><span style="text-decoration: underline; font-family: Shaker2Lancet-Bold; color: #6666CC; letter-spacing: 0px; font-size: 16px;">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext</span></a><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 16px">.</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 19px">相关博文：</span></strong><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"><img class="loadingclass" id="loading_l7o82yag" src="https://blog.sciencenet.cn/static/ueditor/themes/default/images/spacer.gif" title="正在上传..." referrerpolicy="no-referrer"><span style="color: #6666CC; letter-spacing: 0px; font-size: 16px; font-family: Tahoma;">呼吸道合胞病毒疫苗和单抗最新研究进展（１）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-12</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350986" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956961" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>2）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-13</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"></a><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956960" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>3）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-15</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351490" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>4）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-17</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351871" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>5）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-20</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352158" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>6）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-22</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352448" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956959" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>7）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-24</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352713" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956958" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>8）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-26</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956957" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352981" target="_blank"><span style="text-decoration: underline; font-family: Tahoma; color: #6666CC; letter-spacing: 0px; font-size: 16px;"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>9）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-28</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353081" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956956" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>10）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-29</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353361" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956955" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>11）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-08-31</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:16px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353798" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956954" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>12）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-09-03</span></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 16px; background: rgb(255, 255, 255);"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1353965" target="_blank"><img src="http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=956953" title alt="image.png" referrerpolicy="no-referrer"><strong><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>13）</span></strong></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2022-09-04</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1354075.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1354075.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1353965.html" target="_black">呼吸道合胞病毒疫苗和单抗最新研究进展（13）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            